StocksMedium•5 October 2026•
1 min read
Abbott Receives FDA Approval for CardioMEMS HF System Updates
Key Facts
1Abbott received U.S. FDA approval for updates to the CardioMEMS HF System, enabling new patient-facing capabilities through the CardioGuide HF App.
Abbott received U.S. FDA approval for updates to the CardioMEMS HF System, enabling new patient-facing capabilities through the CardioGuide HF App. PR Newswire reported that the updates allow patients to view pulmonary artery pressure readings and receive treatment plan updates directly from their care teams.
The new capabilities include the Dynamic Treatment Plan (DTP), a software feature that enables clinicians to set up personalized medication adjustment plans based on changes in a patient's pulmonary artery pressure. These updates aim to help patients monitor conditions that signal worsening health weeks before symptoms appear, encouraging a more active role in managing heart failure.